ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 202 filers reported holding ACADIA PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is 1.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $153,000 | +35.4% | 3,577 | +14.0% | 0.00% | 0.0% |
| Q3 2019 | $113,000 | +197.4% | 3,137 | +118.6% | 0.00% | – |
| Q2 2019 | $38,000 | -68.9% | 1,435 | -68.4% | 0.00% | -100.0% |
| Q1 2019 | $122,000 | +74.3% | 4,547 | +3.1% | 0.00% | 0.0% |
| Q4 2018 | $70,000 | -32.7% | 4,412 | -11.2% | 0.00% | 0.0% |
| Q3 2018 | $104,000 | +82.5% | 4,967 | +33.8% | 0.00% | 0.0% |
| Q2 2018 | $57,000 | -40.6% | 3,713 | -13.5% | 0.00% | 0.0% |
| Q1 2018 | $96,000 | -30.9% | 4,291 | -6.6% | 0.00% | -50.0% |
| Q4 2017 | $139,000 | +8.6% | 4,596 | +36.1% | 0.00% | 0.0% |
| Q3 2017 | $128,000 | +36.2% | 3,376 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $94,000 | +42.4% | 3,376 | +76.2% | 0.00% | +100.0% |
| Q1 2017 | $66,000 | +1550.0% | 1,916 | +1194.6% | 0.00% | – |
| Q4 2016 | $4,000 | -84.6% | 148 | -81.4% | 0.00% | -100.0% |
| Q3 2016 | $26,000 | +23.8% | 795 | +9.8% | 0.00% | 0.0% |
| Q2 2016 | $21,000 | – | 724 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |